Global access to HPV vaccination: what are we waiting for?

The Lancet

Volumn 374, Issue 9706, 2009, Pages 1948-1949

  Clifford, Gary M ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ANTIBODY TITER; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; FOLLOW UP; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; PERSISTENT INFECTION; PRIORITY JOURNAL; SEXUAL BEHAVIOR; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS INFECTION; WART VIRUS;

EID: 71649114844     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61789-X     Document Type: Note

References (12)

1. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118 (2006) 3030-3044
2. Ferlay J., Bray F., Pisani P., and Parkin D.M. Globocan 2002: incidence, mortality and prevalence worldwide [CD-ROM] (2004), International Agency for Research on Cancer, Lyon
3. Paavonen J., Naud P., Salmerón J., et al., for the HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374 (2009) 301-314
4. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007) 1915-1927
5. Goldie S.J., O'Shea M., Diaz M., and Kim S.Y. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters 16 (2008) 86-96
6. Diaz M., Kim J.J., Albero G., et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 99 (2008) 230-238
7. The GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04 adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years. Lancet (2009) 10.1016/S0140-6736(09)61567-1 published online Dec 3.
8. David M.P., Van Herck K., Hardt K., et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol (2009) 10.1016/j.ygyno.2009.01.011 published online Feb 12.
9. Hildesheim A., Herrero R., Wacholder S., et al., for the Costa Rican HPV Vaccine Trial Group. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298 (2007) 743-753
10. The FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 196 (2007) 1438-1446
11. Kim J.J., Andres-Beck B., and Goldie S.J. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 97 (2007) 1322-1328
12. Jit M., Choi Y.H., and Edmunds W.J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337 (2008) a769